INTERNATIONAL PATENT: CAMP4 THERAPEUTICS CORPORATION FILES APPLICATION FOR "MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS"

GENEVA, Dec. 17 -- CAMP4 THERAPEUTICS CORPORATION (One Kendall Square, Building 1400 West, Third FloorCambridge, Massachusetts 02139) filed a patent application (PCT/US2025/032525) for "MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS" on Jun 05, 2025. With publication no. WO/2025/255388, the details related to the patent application was published on Dec 11, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): AL ABDULLATIF, Ali (c/o CAMP4 Therapeutics CorporationOne Kendall Square, Building 1400 West, Third FloorCambridge, Massachusetts 02139), ...